Related Experiment Videos
Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia
R E Knops1, A A Kroon, M J Mol
1Department of Medicine, St. Radboud University Hospital, Nijmegen, Netherlands.
Insights
Long-term simvastatin treatment effectively lowers cholesterol in familial hypercholesterolaemia patients. This study confirms simvastatin
Area of Science:
- Cardiology
- Pharmacology
- Genetics
Background:
- Familial hypercholesterolaemia is a genetic disorder characterized by high cholesterol levels.
- Effective long-term management is crucial to prevent cardiovascular complications.
Purpose of the Study:
- To assess the long-term efficacy and safety of simvastatin in treating familial hypercholesterolaemia.
- To evaluate simvastatin's impact on lipid profiles over an extended period.
Main Methods:
- Open, long-term follow-up study of 44 patients with heterozygous familial hypercholesterolaemia.
- Patients received simvastatin monotherapy (20-80 mg/day) or combination therapy for 5+ years.
- Baseline mean serum cholesterol was 11.5 mmol/l.
Main Results:
- Mean serum cholesterol reduction of 37.8% over 6 years.
- Significant reductions in LDL-cholesterol (up to 50.3%) and triglycerides.
- Modest increase in HDL-cholesterol (up to 16.2%) with minimal adverse effects.
Conclusions:
- Simvastatin demonstrates sustained efficacy in lowering cholesterol levels.
- The drug is safe for long-term use in familial hypercholesterolaemia patients.
- Simvastatin is a valuable therapeutic option for managing this genetic lipid disorder.
Objective:
To study the long-term efficacy and safety of the cholesterol synthesis inhibitor, simvastatin, in the treatment of familial hypercholesterolaemia.
Methods:
This is an open long-term follow-up of patients treated for 5 years or more in the Nijmegen University lipid clinic. Forty-four patients with heterozygous familial hypercholesterolaemia (mean baseline serum cholesterol level 11.5 mmol/l) were treated with simvastatin alone (monotherapy group) in doses ranging from 20 to 80 mg/day, or in combination with other lipid-lowering agents (combination-therapy group).
Results:
Over the intervention period of 6 years the mean overall reduction of the serum cholesterol level was 37.8% for the total group, 37.7% for the monotherapy group and 42.6% for the combination-therapy group. The reduction of the low-density lipoprotein (LDL)-cholesterol in the three groups was 45.0, 44.6 and 50.3%, respectively. The serum triglyceride concentration was reduced by 14.0, 20.5 and 12.5%, respectively. The increase in the high-density lipoprotein (HDL)-cholesterol level was 14.4, 16.2 and 14.0%, respectively. One patient died from a myocardial infarction and 2 patients had a non-fatal cardiac event. Two patients stopped taking medication due to side-effects (dizziness and insomnia). Biochemical adverse effects were confined to elevations of the alanine aminotransferase level and the creatine phosphokinase level and did not lead to discontinuation of therapy.
Conclusions:
Simvastatin proves to be a safe and effective lipid-lowering drug during long-term treatment.